Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Stoschitzky, K; Stoschitzky, G; Lercher, P; Brussee, H; Lamprecht, G; Lindner, W.
Propafenone shows class Ic and class II antiarrhythmic effects.
Europace. 2016; 18(4):568-571
Doi: 10.1093/europace/euv195
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Stoschitzky Kurt
- Co-Autor*innen der Med Uni Graz
- Brussee Helmut
- Lercher Peter
- Stoschitzky Gergana
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Propafenone is a well-known Class Ic antiarrhythmic agent. It has the typical chemical structure of a beta-blocker, but human studies on its beta-blocking effects revealed conflicting results. Twelve healthy males received single oral doses of 600 mg propafenone and placebo according to a randomized, double-blind, placebo-controlled, cross-over protocol. Four hours following drug intake, heart rate and blood pressure were measured, and plasma concentrations of propafenone were determined at rest, during exercise and after recovery. At exercise, propafenone significantly decreased heart rate (-6%, P < 0.05), systolic blood pressure (-6%, P < 0.05), and the rate-pressure product (-11%, P < 0.05). Plasma concentrations of propafenone increased during exercise (+23%, P < 0.05) and decreased during recovery (-33%, P < 0.05). Both effects on heart rate and blood pressure as well as the changes of plasma concentrations of propafenone during exercise represent two particular features of beta-blockers. Therefore, we conclude that propafenone is both a Class Ic and a Class II antiarrhythmic agent, and 600 mg propafenone, i.e. the dose recommended in current guidelines for cardioversion of paroxysmal atrial fibrillation, cause clinically significant beta-blockade. Thus, single oral doses of 600 mg propafenone appear also suitable for cardioversion of paroxysmal atrial fibrillation in patients with structural heart disease since beta-blockers are explicitly indicated in the treatment of both coronary artery disease and heart failure. Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.
- Find related publications in this database (using NLM MeSH Indexing)
- Administration, Oral -
- Adrenergic beta-Antagonists - administration & dosage
- Adrenergic beta-Antagonists - blood
- Adrenergic beta-Antagonists - classification
- Adrenergic beta-Antagonists - pharmacokinetics
- Adult -
- Anti-Arrhythmia Agents - administration & dosage
- Anti-Arrhythmia Agents - blood
- Anti-Arrhythmia Agents - classification
- Anti-Arrhythmia Agents - pharmacokinetics
- Austria -
- Blood Pressure - drug effects
- Cross-Over Studies -
- Double-Blind Method -
- Drug Monitoring -
- Exercise -
- Exercise Test -
- Healthy Volunteers -
- Heart Rate - drug effects
- Humans -
- Male -
- Molecular Structure -
- Propafenone - administration & dosage
- Propafenone - blood
- Propafenone - classification
- Propafenone - pharmacokinetics
- Recovery of Function -
- Structure-Activity Relationship -
- Young Adult -
- Find related publications in this database (Keywords)
- Atrial fibrillation
- Cardioversion
- Antiarrhythmic drugs
- Beta-blockers
- Propafenone
- Pill-in-the-pocket